Linoleic acid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Linoleic acid
- DrugBank Accession Number
- DB14104
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
- Weight
- Average: 280.4455
Monoisotopic: 280.240230268 - Chemical Formula
- C18H32O2
- Synonyms
- (9Z,12Z)-Octadecadienoic acid
- (Z,Z)-9,12-octadecadienoic acid
- 9-cis,12-cis-Octadecadienoic acid
- 9Z,12Z-octadecadienoic acid
- acide cis-linoléique
- acide linoléique
- ácido linoleico
- all-cis-9,12-octadecadienoic acid
- C18:2 9c, 12c omega6 todos cis-9,12-octadienoico
- cis,cis-9,12-octadecadienoic acid
- cis,cis-linoleic acid
- LA
- Linolic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Acne ••• ••••• Symptomatic treatment of Dermatitis ••• ••••• Symptomatic treatment of Dry skin ••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AFatty acid-binding protein, adipocyte inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Potassium linolate 3S022W5099 3414-89-9 BAYJYBALPIYBQQ-NBTZWHCOSA-M Sodium linolate 872C9A1W9I 822-17-3 WYPBVHPKMJYUEO-NBTZWHCOSA-M - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bio-efa Borage Gla 240 Cap Linoleic acid (378 mg) + Gamolenic acid (240 mg) + Vitamin E (10 unit) Capsule Oral Pge Canada (86) Inc. 1989-12-31 2006-06-19 Canada Bio-efa Borage Gla 90 Cap Linoleic acid (216 mg / cap) + Gamolenic acid (90 mg / cap) + Vitamin E (10 unit / cap) + alpha-Linolenic acid (1 mg / cap) Capsule Oral Pge Canada (86) Inc. 1989-12-31 2006-06-19 Canada Black Currant Seed Oil Cap Linoleic acid (78 mg) + Gamolenic acid (41 mg) + Vitamin E (10 unit) Capsule Oral Pure Life International Prods Inc. 1993-12-31 2001-08-07 Canada Borage Oil Capsules Linoleic acid (375 mg) + Gamolenic acid (258 mg) + Oleic Acid (148 mg) + Palmitic Acid (96 mg) Capsule Oral General Nutrition Canada Inc. 2001-10-15 2009-08-05 Canada Borage Oil Capsules Linoleic acid (220 mg) + Borage oil (500 mg) + Gamolenic acid (125 mg) Capsule Oral Bioforce Canada Inc. 1994-12-31 1999-10-14 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cavan One Linoleic acid (30 mg/1) + Calcium (150 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Cholecalciferol (170 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (260 mg/1) + Ferrous asparto glycinate (7 mg/1) + Folic acid (1 mg/1) + Icosapent (40 mg/1) + Iron (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + alpha-Linolenic acid (30 mg/1) Capsule, gelatin coated Oral Seton Pharmaceuticals 2009-10-30 2011-11-27 US Dr.Different VITAACNAL TX Capsule Serum Linoleic acid (0.76 g/30mL) + Nicotinamide (1.5 g/30mL) Liquid Topical Dareun Cosmetics Co., Ltd. 2021-12-01 Not applicable US Lancell Slimming Linoleic acid (2.5 mL/100mL) + Stypocaulon scoparium (2 mL/100mL) Gel Topical MICELLBio Co., Ltd 2010-08-19 Not applicable US PrimaCare Linoleic acid (50 mg/1) + Biotin (1 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Calcium carbonate (100 mg/1) + Cholecalciferol (1000 [iU]/1) + Folic acid (1 mg/1) + Magnesium oxide (50 mg/1) + Nicotinamide (10 mg/1) + Omega-3 fatty acids (420 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine (50 mg/1) + Riboflavin (1.5 mg/1) + Zinc (15 mg/1) + alpha-Tocopherol acetate (15 [iU]/1) Pill Oral Avion Pharmaceuticals, Llc 2017-01-23 Not applicable US SIMILAC ALIMENTUM 400 G TOZ Linoleic acid (0.54 g/100ml) + Arachidonic Acid (0.013 g/100ml) + Doconexent (0.007 g/100ml) + alpha-Linolenic acid (0.058 g/100ml) ABBOTT LABORATUARLARI İTHALAT İHRACAT VE TİC. LTD. ŞTİ. 2015-08-18 Not applicable Turkey
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9KJL21T0QJ
- CAS number
- 60-33-3
- InChI Key
- OYHQOLUKZRVURQ-HZJYTTRNSA-N
- InChI
- InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-
- IUPAC Name
- (9Z,12Z)-octadeca-9,12-dienoic acid
- SMILES
- CCCCC\C=C/C\C=C/CCCCCCCC(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000673
- KEGG Compound
- C01595
- ChemSpider
- 4444105
- BindingDB
- 22231
- 6400
- ChEBI
- 17351
- ChEMBL
- CHEMBL267476
- ZINC
- ZINC000004474613
- PDBe Ligand
- EIC
- Wikipedia
- Linoleic_acid
- PDB Entries
- 1igz / 2evl / 2q9s / 4dq4 / 4ia6 / 4lkt / 4nyq / 5bvs / 5z0b / 6cng … show 31 more
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Supportive Care Malnutrition 1 somestatus stop reason just information to hide 4 Completed Treatment Patients Requiring Home Parenteral Nutrition 1 somestatus stop reason just information to hide 3 Completed Treatment Gastrointestinal Tract Cancer 1 somestatus stop reason just information to hide 2 Completed Prevention Parenteral Nutrition n-3 Fatty Acids / Preterm, Infant 1 somestatus stop reason just information to hide 2, 3 Active Not Recruiting Treatment Neuroaxonal Dystrophy, Infantile 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, gelatin coated Oral Liquid Topical Liquid Oral Gel Topical Injection, emulsion Intravenous Tablet, coated Oral Pill Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000154 mg/mL ALOGPS logP 7.06 ALOGPS logP 6.42 Chemaxon logS -6.3 ALOGPS pKa (Strongest Acidic) 4.99 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 88.52 m3·mol-1 Chemaxon Polarizability 35.86 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 207.8025395 predictedDarkChem Lite v0.1.0 [M-H]- 179.0616621 predictedDarkChem Standard v0.1.0 [M-H]- 208.1904395 predictedDarkChem Lite v0.1.0 [M-H]- 207.4887395 predictedDarkChem Lite v0.1.0 [M-H]- 178.93639 predictedDeepCCS 1.0 (2019) [M+H]+ 181.29442 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.33626 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsFatty acid-binding protein, adipocyte
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus
- Specific Function
- fatty acid binding
- Gene Name
- FABP4
- Uniprot ID
- P15090
- Uniprot Name
- Fatty acid-binding protein, adipocyte
- Molecular Weight
- 14718.815 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at June 21, 2018 16:16 / Updated at August 26, 2024 19:22